Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design

被引:182
作者
Verhoeven, BAN
Velema, E
Schoneveld, AH
de Vries, JPPM
de Bruin, P
Seldenrijk, CA
de Kleijn, DPV
Busser, E
van der Graaf, Y
Moll, F
Pasterkamp, G
机构
[1] Univ Utrecht, Med Ctr, Lab Expt Cardiol, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Vasc Surg, NL-3584 CX Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Julius Ctr, NL-3584 CX Utrecht, Netherlands
[4] St Antonius Hosp, Dept Vasc Surg, Nieuwegein, Netherlands
[5] St Antonius Hosp, Dept Pathol, Nieuwegein, Netherlands
关键词
atherosclerosis; cardiovascular event; endarterectomy; inflammation; vulnerable plaque;
D O I
10.1007/s10564-004-2304-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In clinical practice, biological markers are not available to routinely assess the progression of atherosclerotic disease or the development of restenosis following endarterectomy or catheter based interventions. Endarterectomy procedures provide an opportunity to study mechanisms of restenosis and progression of atherosclerotic disease since atherosclerotic tissue is obtained. Athero-Express is an ongoing prospective study, initiated in 2002, with the objective to investigate the etiological value of plaque characteristics for long term outcome. Patients are included who undergo an endarterectomy of the carotid artery. At baseline blood is withdrawn, patients fill in an extensive questionnaire and diagnostic examinations are performed. Atherosclerotic plaques are freshly harvested, immunohistochemically stained and examined for the presence of macrophages, smooth muscle cells, collagen and fat. Parts of the atherosclerotic plaques are freshly frozen to study protease activity and protein and RNA expressions. Patients undergo a duplex follow up to assess procedural restenosis (primary endpoint) at 3 months, I year and 2 years. Secondary endpoints encompass major adverse cardiovascular events. In the future, the creation of this biobank with atherosclerotic specimen will allow the design of cross-sectional and follow up studies with the objective to investigate the expression of newly discovered genes and proteins and their interaction with patients and plaque characteristics in the progression of atherosclerotic disease. Objective is to include 1000-1200 patients in 5 years. In January 2004, 289 patients had been included. It is expected that 250 patients will be included yearly.
引用
收藏
页码:1127 / 1133
页数:7
相关论文
共 26 条
[21]  
TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
[22]  
TORVIK A, 1982, CLIN NEUROPATHOL, V1, P99
[23]   SITE OF INTIMAL RUPTURE OR EROSION OF THROMBOSED CORONARY ATHEROSCLEROTIC PLAQUES IS CHARACTERIZED BY AN INFLAMMATORY PROCESS IRRESPECTIVE OF THE DOMINANT PLAQUE MORPHOLOGY [J].
VANDERWAL, AC ;
BECKER, AE ;
VANDERLOOS, CM ;
DAS, PK .
CIRCULATION, 1994, 89 (01) :36-44
[24]  
Veith FJ, 2001, J VASC SURG, V33, pS111
[25]   MRC-EUROPEAN-CAROTID-SURGERY-TRIAL - INTERIM RESULTS FOR SYMPTOMATIC PATIENTS WITH SEVERE (70-99-PERCENT) OR WITH MILD (0-29-PERCENT) CAROTID STENOSIS [J].
WARLOW, C .
LANCET, 1991, 337 (8752) :1235-1243
[26]   Serologic markers of persistent Chlamydia pneumonia infection and long-term prognosis after successful coronary stenting [J].
Zairis, MN ;
Papadaki, OA ;
Psarogianni, PK ;
Thoma, MA ;
Andrikopoulos, GK ;
Batika, PC ;
Poulopoulou, CG ;
Trifinopoulou, KG ;
Olympios, CD ;
Foussas, SG .
AMERICAN HEART JOURNAL, 2003, 146 (06) :1082-+